Viela Bio (NYSE:VIE) Issues Quarterly Earnings Results, Misses Expectations By $6.54 EPS

Viela Bio (NYSE:VIE) released its earnings results on Wednesday. The company reported ($6.87) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($6.54), Fidelity Earnings reports.

Viela Bio stock opened at $32.84 on Thursday. The firm has a 50 day moving average price of $41.20. Viela Bio has a 12 month low of $18.20 and a 12 month high of $70.66.

A number of research analysts have recently commented on VIE shares. HC Wainwright initiated coverage on Viela Bio in a report on Tuesday, February 18th. They set a “buy” rating and a $60.00 price target for the company. Goldman Sachs Group cut shares of Viela Bio from a “buy” rating to a “neutral” rating and set a $36.00 target price for the company. in a research note on Tuesday, February 4th. Zacks Investment Research cut shares of Viela Bio from a “buy” rating to a “hold” rating in a research note on Friday, February 21st. Finally, Morgan Stanley increased their price target on shares of Viela Bio from $25.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Viela Bio has a consensus rating of “Buy” and an average price target of $43.60.

About Viela Bio

Viela Bio, Inc, a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company is developing inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; kidney transplant desensitization; myasthenia gravis; and IgG4-related diseases.

Featured Story: What is the 52-week high/low?

Receive News & Ratings for Viela Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viela Bio and related companies with's FREE daily email newsletter.